Search company, investor...

Bright Angel Therapeutics

Submit Your Analyst Briefing

Founded Year



Seed VC - II | Alive

About Bright Angel Therapeutics

Bright Angel Therapeutics is focused on the development of novel therapeutics for the treatment of drug-resistant and life-threatening fungal infections.

Headquarters Location

Toronto, Ontario,


Missing: Bright Angel Therapeutics's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Bright Angel Therapeutics's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Latest Bright Angel Therapeutics News

Bright Angel: New hope against fungal resistance

Apr 15, 2019

Bright Angel: New hope against fungal resistance How Bright Angel's HSP90 inhibitor could block antifungal resistance 3:45 PM Share PDF Bright Angel is tackling antifungal resistance at its root with inhibitors of Hsp90 and other stress response factors, unlike competitors that are developing compounds against known or new pathways where resistance can still emerge. Resistance to the three approved classes of antifungal agents -- azoles, polyenes and echinocandins -- is a growing problem, yet most compounds in development trod the same biological pathways as those classes. According to Bright Angel Therapeutics Inc. co-founder and CSO Leah Cowen, fungal and human proteins, such as Hsp90, share a high degree of homology, raising the potential for toxicity that hampers the development of new targets. Cowen also is a professor of molecular genetics at the University of Toronto. In a series of papers between 2005 and 2018, Cowen and the late Susan Lindquist reported that Hsp90 and other fungal proteins at the nexus of stress responses promoted drug tolerance and resistance. Lindquist was a director at the Whitehead Institute for Biomedical Research and Cowen was... Read the full 787 word article User Sign in

Bright Angel Therapeutics Frequently Asked Questions (FAQ)

  • When was Bright Angel Therapeutics founded?

    Bright Angel Therapeutics was founded in 2017.

  • Where is Bright Angel Therapeutics's headquarters?

    Bright Angel Therapeutics's headquarters is located at Toronto.

  • What is Bright Angel Therapeutics's latest funding round?

    Bright Angel Therapeutics's latest funding round is Seed VC - II.

  • Who are the investors of Bright Angel Therapeutics?

    Investors of Bright Angel Therapeutics include Lumira Ventures, Viva Biotech, Toronto Innovation Acceleration Partners and Schrodinger.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.